(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 105.78% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Plus Therapeutics's revenue in 2026 is $5,258,000.On average, 7 Wall Street analysts forecast PSTV's revenue for 2026 to be $1,091,736,413, with the lowest PSTV revenue forecast at $538,721,896, and the highest PSTV revenue forecast at $2,251,087,921. On average, 6 Wall Street analysts forecast PSTV's revenue for 2027 to be $3,283,454,982, with the lowest PSTV revenue forecast at $2,046,043,771, and the highest PSTV revenue forecast at $4,040,414,217.
In 2028, PSTV is forecast to generate $6,499,982,014 in revenue, with the lowest revenue forecast at $5,410,032,179 and the highest revenue forecast at $7,936,527,926.